9 stories about NeuraLight
Generative AI Chip

Holiday reading recommendation: 7 tech leaders using AI for social impact

11.04.23|Michael Matias and Betty Elbert
The recent calls to stop the development of systems based on artificial intelligence (AI) due to "fundamental risk to humanity" led us to return to interviews with several leaders who make a contribution to humanity thanks to AI technologies.
Peeches Mind the tech NY conference Micha Breakstone

NeuraLight: Helping accelerate and improve drug development

NeuroSense & NeuraLight  R&D Teams

NeuroSense Therapeutics and NeuraLight collaborate to detect ALS using AI

The collaboration between the Israeli companies will help the scientific community better understand Amyotrophic lateral sclerosis (ALS) and develop effective drugs to treat it
NeuraLight team

NeuraLight secures $25 million Series A to develop precision medicine for neurological diseases

24.05.22|Meir Orbach
The company leverages oculometric data and uses computer vision and smartphones to measure the progression of neurological disorders such as Alzheimer’s, Parkinson’s, MS, and ALS
Micha Breakstone NeuraLight 20

“We want to hire people that make us an integral part of their life.”

When Micha Breakstone and his co-founder were building NeuraLight, they knew how important it was to set the company’s values first.
Gil Shklarski Neuralight

NeuraLight appoints Dr. Gil Shklarski as Scientific Co-founder and Board Observer

16.01.22|James Spiro
Before joining NeuraLight, Dr. Shklarski served as CTO of Flatiron Health, a healthtech company focused on cancer treatment and research
Micha Breakstone BiblioTech

CTech's Book Review: Understanding the 6 critical questions for leadership teams

09.01.22|Micha Breakstone
Micha Breakstone Co-Founder and CEO of, shares insights after reading “The Advantage: Why Organizational Health Trumps Everything Else In Business” by Patrick Lencioni
NeuraLight Team

NeuraLight launches from stealth, raises $5.5 million to digitize neurology

31.10.21|James Spiro
After selling to ZoomInfo for $575 million, co-founder Micha Breakstone is on to his next challenge
מיכה ברקסטון NeuraLight

How can startups leverage controversial FDA approval for Alzheimer’s drug?

17.06.21|Dr. Micha Breakstone
The decision to approve Biogen's Alzheimer’s drug signifies a watershed moment for neurology, highlighting an unprecedented opportunity for neurology-focused startups